FF-10832 liposomal gemcitabine monotherapy or combination with pembrolizumab in patients with advanced non–small cell lung cancer. Landmark survival analysis from 4 years after ICI initiation (n=235).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results